1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
insider
insider
Articles 

Camber Capital Management LLC Buys HCA Healthcare Inc, Gilead Sciences Inc, Mylan NV, Sells Global Blood Therapeutics Inc, Biogen Inc, NuVasive Inc

Boston, MA, based Investment company Camber Capital Management LLC (Current Portfolio) buys HCA Healthcare Inc, Gilead Sciences Inc, Mylan NV, United Therapeutics Corp, DaVita Inc, sells Global Blood Therapeutics Inc, Biogen Inc, NuVasive Inc, Clovis Oncology Inc, Alexion Pharmaceuticals Inc during the 3-months ended 2019Q2, according to the most recent filings of the investment company, Camber Capital Management LLC. As of 2019Q2, Camber Capital Management LLC owns 30 stocks with a total value of $2.1 billion. These are the details of the buys and sells.

For the details of Camber Capital Management LLC's stock buys and sells, go to https://www.gurufocus.com/guru/camber+capital+management+llc/current-portfolio/portfolio

These are the top 5 holdings of Camber Capital Management LLC
  1. SPDR S&P 500 ETF Trust (SPY) - 1,000,000 shares, 13.82% of the total portfolio.
  2. Allergan PLC (AGN) - 1,250,000 shares, 9.87% of the total portfolio. Shares reduced by 3.85%
  3. Mylan NV (MYL) - 9,250,000 shares, 8.31% of the total portfolio. Shares added by 60.87%
  4. DaVita Inc (DVA) - 2,000,000 shares, 5.31% of the total portfolio. Shares added by 33.33%
  5. Perrigo Co PLC (PRGO) - 2,000,000 shares, 4.49% of the total portfolio. Shares reduced by 4.76%
New Purchase: HCA Healthcare Inc (HCA)

Camber Capital Management LLC initiated holding in HCA Healthcare Inc. The purchase prices were between $112.01 and $135.18, with an estimated average price of $126.22. The stock is now traded at around $122.87. The impact to a portfolio due to this purchase was 3.83%. The holding were 600,000 shares as of .

New Purchase: Gilead Sciences Inc (GILD)

Camber Capital Management LLC initiated holding in Gilead Sciences Inc. The purchase prices were between $61.87 and $69.38, with an estimated average price of $65.76. The stock is now traded at around $63.55. The impact to a portfolio due to this purchase was 3.19%. The holding were 1,000,000 shares as of .

New Purchase: United Therapeutics Corp (UTHR)

Camber Capital Management LLC initiated holding in United Therapeutics Corp. The purchase prices were between $76.06 and $120.81, with an estimated average price of $93.52. The stock is now traded at around $81.04. The impact to a portfolio due to this purchase was 1.35%. The holding were 367,529 shares as of .

New Purchase: GlaxoSmithKline PLC (GSK)

Camber Capital Management LLC initiated holding in GlaxoSmithKline PLC. The purchase prices were between $38.64 and $41.88, with an estimated average price of $40.14. The stock is now traded at around $40.35. The impact to a portfolio due to this purchase was 0.94%. The holding were 500,000 shares as of .

New Purchase: Cyclerion Therapeutics Inc (CYCN)

Camber Capital Management LLC initiated holding in Cyclerion Therapeutics Inc. The purchase prices were between $9.6 and $22.85, with an estimated average price of $14.45. The stock is now traded at around $8.44. The impact to a portfolio due to this purchase was 0.84%. The holding were 1,561,915 shares as of .

New Purchase: TG Therapeutics Inc (TGTX)

Camber Capital Management LLC initiated holding in TG Therapeutics Inc. The purchase prices were between $6.27 and $8.65, with an estimated average price of $7.56. The stock is now traded at around $6.70. The impact to a portfolio due to this purchase was 0.41%. The holding were 1,000,000 shares as of .

Added: Mylan NV (MYL)

Camber Capital Management LLC added to a holding in Mylan NV by 60.87%. The purchase prices were between $16.8 and $28.47, with an estimated average price of $22.14. The stock is now traded at around $19.16. The impact to a portfolio due to this purchase was 3.14%. The holding were 9,250,000 shares as of .

Added: DaVita Inc (DVA)

Camber Capital Management LLC added to a holding in DaVita Inc by 33.33%. The purchase prices were between $43.42 and $57.79, with an estimated average price of $51.75. The stock is now traded at around $56.20. The impact to a portfolio due to this purchase was 1.33%. The holding were 2,000,000 shares as of .

Added: Teva Pharmaceutical Industries Ltd (TEVA)

Camber Capital Management LLC added to a holding in Teva Pharmaceutical Industries Ltd by 85.71%. The purchase prices were between $8.12 and $15.72, with an estimated average price of $12.08. The stock is now traded at around $7.05. The impact to a portfolio due to this purchase was 1.31%. The holding were 6,500,000 shares as of .

Added: Ascendis Pharma A/S (ASND)

Camber Capital Management LLC added to a holding in Ascendis Pharma A/S by 51.16%. The purchase prices were between $107.11 and $132.09, with an estimated average price of $119.62. The stock is now traded at around $114.07. The impact to a portfolio due to this purchase was 1.19%. The holding were 650,000 shares as of .

Added: Nektar Therapeutics Inc (NKTR)

Camber Capital Management LLC added to a holding in Nektar Therapeutics Inc by 25.00%. The purchase prices were between $31 and $36.3, with an estimated average price of $33.41. The stock is now traded at around $17.28. The impact to a portfolio due to this purchase was 0.84%. The holding were 2,500,000 shares as of .

Added: Tenet Healthcare Corp (THC)

Camber Capital Management LLC added to a holding in Tenet Healthcare Corp by 42.86%. The purchase prices were between $19.96 and $31.19, with an estimated average price of $23.04. The stock is now traded at around $20.67. The impact to a portfolio due to this purchase was 0.73%. The holding were 2,500,000 shares as of .

Sold Out: Global Blood Therapeutics Inc (GBT)

Camber Capital Management LLC sold out a holding in Global Blood Therapeutics Inc. The sale prices were between $52.6 and $63.29, with an estimated average price of $57.46.

Sold Out: Biogen Inc (BIIB)

Camber Capital Management LLC sold out a holding in Biogen Inc. The sale prices were between $219.29 and $241.72, with an estimated average price of $230.78.

Sold Out: NuVasive Inc (NUVA)

Camber Capital Management LLC sold out a holding in NuVasive Inc. The sale prices were between $53.69 and $65.47, with an estimated average price of $58.97.

Sold Out: Clovis Oncology Inc (CLVS)

Camber Capital Management LLC sold out a holding in Clovis Oncology Inc. The sale prices were between $12.81 and $25.67, with an estimated average price of $18.09.

Sold Out: Eagle Pharmaceuticals Inc (EGRX)

Camber Capital Management LLC sold out a holding in Eagle Pharmaceuticals Inc. The sale prices were between $46.61 and $58.45, with an estimated average price of $52.12.



Here is the complete portfolio of Camber Capital Management LLC. Also check out:

1. Camber Capital Management LLC's Undervalued Stocks
2. Camber Capital Management LLC's Top Growth Companies, and
3. Camber Capital Management LLC's High Yield stocks
4. Stocks that Camber Capital Management LLC keeps buying

Rating: 0.0/5 (0 votes)

Comments

Please leave your comment:



Performances of the stocks mentioned by insider


User Generated Screeners


pjmason14Momentum
pascal.van.garsseHigh FCF-M2
kosalmmuse6
kosalmmuseBest one1
DBrizanall 2019Feb26
kosalmmuseBest one
DBrizanall 2019Feb25
kosalmmuseNice
kosalmmusehan
MsDale*52-Week Low
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)